Clare J. Twist
Key Documents
Contact Information
-
Clinical Offices
Pediatric Hematology/Oncology 2516 Stockton Blvd Ticon II Building Sacramento, CA 95817 Tel Work (650) 497-8953 Fax (650) 497-8101Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5535Alternate Contact Verenna McFarland Administrative Assistant Email Tel Work 6507235535Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Hematology/Oncology/Stem Cell Transplant, Pediatric
- Oncology (Cancer), Pediatric
- Pediatric Hematology-Oncology
Professional Education
| Fellowship: | Children's Hospital Boston MA (1993) |
| Board Certification: | Pediatric Hematology-Oncology, American Board of Pediatrics (1994) |
| Residency: | Children's Memorial Hospital IL (1990) |
| Internship: | Children's Memorial Hospital IL (1988) |
| Medical Education: | Albany Medical Center NY (1987) |
Scientific Focus
Current Research Interests
My primary research interest is in the study and treatment of neuroblastoma. My clinical interests also include Wilms tumor, hepatoblastoma, post-transplant lymphoproliferative disorders, phase I therapies for hematologic malignancies, as well as palliative and end of life care.
As a clinical investigator in the Children's Oncology Group (COG), I am involved in the clinical trial design of treatment protocols for patients with neuroblastoma, and am the Study Chair for the current COG Phase III Study for the treatment of children with Intermediate Risk Neuroblastoma. I am also the Principal Investigator at Stanford for the New Advances in Neuroblastoma (NANT) Consortium, a limited institution consortium which develops Phase I trials of novel therapies for patients with high risk and recurrent neuroblastoma. I am also interested in new therapies for the treatment of hematologic malignancies and am the Principal Investigator at Stanford for the Therapeutic Advances in Childhood Leukemia (TACL) Consortium, another limited institution consortium specifically dedicated to the development of novel therapies for relapsed leukemias.
Clinical Trials
- Bevacizumab, Cyclophosphamide, and Zoledronic Acid in Treating Patients With Recurrent or Refractory High-Risk Neuroblastoma Recruiting
- Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Recruiting
- Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Recruiting
- Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Recruiting
- Vorinostat and Iobenguane I 131 in Treating Patients With Resistant or Relapsed Neuroblastoma Recruiting
Publications
- Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010; (4): 648-54
- Detection of isolated tumor cells in neuroblastoma by immunohistochemical analysis in bone marrow biopsy specimens: improved detection with use of beta-catenin. Am J Clin Pathol. 2009; (1): 49-57
- 123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma. Mol Imaging Biol. 2008 Jan-Feb; (1): 19-23
- Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008; (2): 381-3
- Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Pediatr Blood Cancer. 2007; (4): 380-6
Help